IDH1 and central nervous system cancer: No mutations of IDH3, which normally catalyse the same reaction as IDH1/IDH2 (but use NAD+ as substrate) have been noted in gliomas, so the consequence of its downregulation can only be extrapolated from reports on IDH1/IDH2.